HENAN NEW BLUE CHEMICAL CO.,LTD

Pharmaceutical Agrochemicals Food Additives Synthetic Flavours & Fragrances Plant Extract Adhesive and Sealant Catalyst and Auxiliary Dyestuff and Pigment Materials Basic Inorganic Chemicals Organic Chemicals Others Reagent

HENAN NEW BLUE CHEMICAL CO.,LTD

Country: China (Mainland)Business Type: Lab/Research institutions

Manufacturer

Assessed supplierAssessed
supplier

qq

    x
  • Mr.Nolan
  • Ms. Jane Kong

Products Categories
Contact US
Mr.Nolan
Tel: 0371-55170695
  • Fax: 86-371-55170690
  • URL: http://www.newbluechem.com
  • Province/state: Henan
  • City: Zhengzhou
  • Street:Zhengzhou International Trade New Territory,Jinshui District,Zhengzhou ,China
  • MaxCard:
Home > Products > 

C17H20F2N4O3S Omarigliptin (MK-3102) 1226781-44-7

C17H20F2N4O3S Omarigliptin (MK-3102) 1226781-44-7 CAS NO.1226781-44-7

  • Min.Order: 1 Metric Ton
  • Payment Terms: L/C,T/T,
  • Product Details

Keywords

  • Omarigliptin (MK-3102)
  • 1226781-44-7
  • C17H20F2N4O3S

Quick Details

  • ProName: C17H20F2N4O3S Omarigliptin (MK-3102...
  • CasNo: 1226781-44-7
  • Molecular Formula: C17H20F2N4O3S
  • Appearance: Powder
  • Application: 1226781-44-7
  • DeliveryTime: by air
  • PackAge: Aluminium Foil Bag and Paper Drum
  • Port: Any port of China
  • ProductionCapacity: 100 Metric Ton/Day
  • Purity: 99.5%
  • Storage: 1MT
  • Transportation: By Sea/Air/DHL
  • LimitNum: 1 Metric Ton
  • Grade: Industrial Grade,Food Grade,Pharma Gra...

Superiority

Our company was built in 2009 with an ISO certificate.In the past 5 years, we have grown up as a famous fine chemicals supplier in China and we had established stable business relationships with Samsung,LG,Merck,Thermo Fisher Scientific and so on.Our main business covers the fields below:

 

1.Noble Metal Catalysts (Pt.Pd...)

2.Organic Phosphine Ligands (Tert-butyl-phosphine.Cyclohexyl-phosphine...)

3.OLED intermediates (Fluorene,Carbazole,Boric acid...)

4.Customs Synthesis

 

Our advantage:

1. Higest quality and good package

2.Fast delivery

3.Better payment term

4.Fast response to customer  within 6 hours

5.Good business credit in Europe ,US ,Japan ,Korea

 

Anyway ,if you need any chemicals from China ,Henan Tianfu can help you

Details

Omarigliptin (MK-3102) Basic information
Oral hypoglycemic agents Clinical evaluation Market expectation
Product Name: Omarigliptin (MK-3102)
Synonyms: MK-3102;(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(Methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-aMine;MK-3012;(2S,3R,5S)-2-(2,5-Difluorophenyl)-5-[2-(Methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-aMine (MK-3102 enantioMer);(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine;OMarigliptin;OMarigliptin (MK-3102);2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine MK3102
CAS: 1226781-44-7
MF: C17H20F2N4O3S
MW: 398.43
EINECS:  
Product Categories: API;Inhibitors
Mol File: 1226781-44-7.mol
Omarigliptin (MK-3102) Structure
 
Omarigliptin (MK-3102) Chemical Properties
 
Safety Information
MSDS Information
 
 
Omarigliptin (MK-3102) Usage And Synthesis
Oral hypoglycemic agents Omarigliptin (MK-3102) is an oral hypoglycemic agent of super long-lasting dipeptidyl peptidase-4 (DPP-4) developed by Merck & Co., USA. It is administered orally once a week, being able to produce sustained DPP-4 inhibition with a new mechanism of lowering blood sugar. Meanwhile, it does not increase body weight and not cause hypoglycemia and edema. Its mechanism of action is through inhibiting the degrading of the in vivo dipeptidyl peptidase-4 (DPP-4) on the GLP-1, prolonging the action time of glucagon-like peptide-1 (GLP-1), thereby increasing the blood concentration of the endogenous GLP-1 and GIP, and ultimately improving blood glucose control.
GLP-1 is a class of incretin, belonging to a moderate-length straight-chain peptide hormone with insulin secretion promoting effect generated in the intestine. Its action features include: merely postprandial production, promoting insulin secretion by islet β-cells and further lowing the blood sugar level but without triggering the hypoglycemia; it can inhibit the pancreatic α cells from secreting the glucagon; delay the gastric emptying which is good for the postprandial blood glucose control; it can cause inhibition of intestinal secretion of lipoproteins and may reduce the postprandial hyperglycemia which is risk factors for cardiovascular disease, thus playing a heart protection effect.
Omarigliptin is a kind of DPP-4 inhibitor oral hypoglycemic agents administrated once weekly, improving the drug compliance. Poor adherence to medication is a common problem in clinical practice, particularly in chronic asymptomatic diseases such as type 2 diabetes, dyslipidemia, and hypertension. For the patients of type II diabetes, improving the adherence to medication is critical to maintaining good glycemic control during long-term treatment, thereby preventing the development of type 2 diabetes and the development and progression of complications.
On September 19, 2014, Merck published the first data on the Phase III clinical development of omarigliptin in the treatment of type 2 diabetes at the 50th annual European Diabetes Association (EASD) annual meeting. Compared with placebo, omarigliptin can significantly reduce the HbA1c levels, meanwhile being able to achieve equal efficacy and tolerability to a 50-mg daily dose of the DPP-4 inhibitor Januvir (Sigma).
In December 2014, Merck has submitted an experimental new drug application (NDA) of the hypoglycemic drug omarigliptin to the Japanese Pharmaceutical and Medical Device Agency (PMDA), marking the world's first regulatory application.
Clinical evaluation (1) Pharmacodynamic properties. The inhibitory activity of Omarigliptin on DPP-4 (C50 = 1.6 nM, K1 = 0.8 nM) is stronger than that of sitagliptin (IC50 = 18 nM).
(2) High selectivity to DPP-4. DPP has many subtypes from 1-9, of which the inhibition constant of DPP-8 and DPP-9 are often related with the toxic effects of drugs. Two weeks of rat studies have shown that inhibition of DPP-8 and DPP-9 can lead to increased hair loss, thrombocytopenia, anemia, splenomegaly and even death cases in rats. In acute dog toxicity studies, inhibition resulted in bloody diarrhea in dogs. In vitro studies have shown that Omarigliptin is very specific for DPP-4 inhibition and has very low activity against the remaining proteases (including QPP, FAP, FEF, DPP8 and DPP9) with IC50> 67 μM and thus does not produce the above-mentioned side effects.
(3) In the aspect of pharmacokinetics, the most significant feature of Omarigliptin is a long half-life of up to 63h while the value for sitagliptin is 12.4h, for vildagliptin is 2-3 h and for saxagliptin in the parent body is 2.5 h. This means that Omarigliptin only needs to be taken once a week to achieve better glycemic control effect.
(4) In the aspect of usage range, renal insufficiency has effects on the in vivo exposure level and clearance rate of the omarigliptin, so we may need to adjust the dosage and usage of the drug. This may be similar to other DPP-4 inhibitors such as sitagliptin, vildagliptin and saxagliptin.
Comparatively, the advantage of omarigliptin is obvious, which has excellent PK/PD, efficacy and safety with excellent potential during the clinical treatment.
Market expectation Diabetes is caused by the effects of genetic factors, immune dysfunction, microbial infection and toxins, free radical toxins, mental factors, and various kinds of pathogenic factors on the body that lead to islet dysfunction, insulin resistance, further causing a series metabolic disorders of sugar, protein, fat, water and electrolytes. It is clinically mainly characterized by the high blood sugar. In typical cases, there may be polyuria, polydipsia, more food, weight loss and other performance, namely "three polys and one little" symptoms, Blood sugar, once not controlled well, will lead to poor diabetes complications, leading to the failure of lesions in kidney, eye, foot and other parts and can’t be cured.
China is a big country of diabetes. According to the latest research results, in the samples of China's 18-year-old and adult, the estimated prevalence of diabetes was 11.6%, about 113.9 million people. The pre-diabetes (IGT) prevalence rate in Chinese adults is about 50.1%, namely, half of the people is the reserve of diabetes. This figure is very alarming, indicates that China's diabetes situation is very serious.
DPP-4 inhibitors are the host spots at both home and abroad in recent years. The number listed abroad has already reached 7. There are also a number of domestic 1.1 class novel drug of independent research and development having obtained clinical approval documents. The first marketed DPP-4 inhibitor is sitagliptin, with sales currently being $ 4 billion and is expected to reach $ 7.8 billion by 2018.
The pharmacological effects, clinical evaluation, indications, and market prospects of oral hypoglycemic agents, omarigliptin, are compiled by the editor, tontong of the Chemicalbook (2015-09-22).

 

Other products of this supplier

CAS No.1 2 3 4 5 6 7 8 9 50-00-0 To 1540426-95-6

Chemicals A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 1 2 3 4 5 6 7 8 9

HENAN NEW BLUE CHEMICAL CO.,LTDTel:0371-55170695 Fax:86-371-55170690  Email:info@newbluechem.com
 Address:Zhengzhou International Trade New Territory,Jinshui District,Zhengzhou ,China,450000